VL and VH of pKscFv were cloned into the vector pDscFv to prepare pDKscFv. Enzymatic digestion and sequencing confirmed that pDKscFv was obtained successfully. Keratin binding activity of the expressed phage antibodies was determined by ELISA. The results demonstrated that after the replacement of the linker, scFv remained its specific binding activity to keratin without changing in binding affinity.
One pDKscFv clone was selected to extract plasmids. Following digestion with Acc III, the products ligated spontaneously. Enzymatic digestion and sequencing of the extracted plasmids confirmed that the short linkers were successfully obtained. The expression phage antibody supernatants were subjected to analysis of antigen-binding specificity by ELISA. The results demonstrated that the linkers with 5 amino acid residues kept their binding activities high (Fig. 4).
The different V-region genes of obtained antibodies against six antigens were sequenced. Sequence analysis and homology comparison were carried out with the Pcgene software. The results demonstrated a high diversity, with the light-chain genes belonging to subgroups VĪ» I, VĪ» II and VĪ» III and the heavy chain genes belonging to subgroups VH1, VH2, VH3 and VH4, respectively.
One clone was selected from the anti-digoxin scFv to construct diabody. Plasmids were digested with Acc III and then ligated spontaneously. Enzymatic digestion and sequencing analysis confirmed the presence of a 15 bp short linker. Then the recombinant was induced to express, and the supernatant was subjected to antigen-binding specificity analysis by ELISA. The results demonstrated that its activity remained unchanged, suggesting the generation of functional diabodies, which is potentially important for clinical diagnosis and treatment of digoxin toxication.
In order to investigate the effect of reconstruction on vector functions, we evaluated the recombination capability of the reconstructed vector, the binding activity of scFv, and the feasibility of diabody construction. The results showed that the two designed restriction sites did not change the Loxp511 sequence and its site-specific recombination capability. A large antibody library can ever be constructed with the intracellular recombination method but no influence on scFv's binding activity. The design of scFv linker may be significant to maintain the binding activity of parent antibody. Most linkers are reported to comprise 14-15 amino acid residues. Currently the most widely used linker comprises four glycine residues and one serine residue (GGGGS)3.20 Glycine has the smallest molecular weight and the shortest side-chain, and serine is a hydrophilic amino acid, which can increase the linker's hydrophilicity. The sequence of the amino acid encoded by loxp511 was ITSYNVYYTKL, which can be used as a scFv linker with no influence on the scFv's antigen-binding activity. In the present study, restriction sites were introduced on both sides of the loxp511 sequence to conveniently construct diabodies. As a result, the length of scFv linker was increased to 21 amino acids. The introduced amino acid sequences were SGGST and SGGGT, both comprising hydrophilic amino acids. The original pKscFv linker was SR (GGGGS)3.10 After sequence modifications, scFv's antigen-binding activity remained unchanged.
Shortening of the linker between VL and VH can pair VL and VH of different molecules to form diabody. The linker length is a key to the formation of diabodies. Previous studies21,22 showed that diabodies dominate when the linker is composed of 3-12 amino acid residues, structures similar to scFv dominate when the linker is composed of more than 12 amino acid residues, and trimers or multimers are likely to form when the linker is composed of 1 or 2 amino acid residue(s). Presently the majority of diabodies have linkers comprising 5-6 amino acid residues.23,24 The frequently reported linker peptide has a length of 5 amino acid residues, namely, GGGGS.20,25 In this study, the linker of diabody comprised 5 amino acid residues, that is, SGGGT. Analysis with anti-keratin and anti-digoxin scFv confirmed that the linker can be used to construct ordinary diabodies.
REFERENCES
1. Aujame L, Geoffroy F, Sodoyer R. High affinity human antibodies by phage display. Hum Antibodies 1997; 8: 155-168.
2. Sheets MD, Amersdorfer P, Finnern R, Sargent P, Lindquist E, Schier R, et al. Efficient construction of a large nonimmune
phage antibody library: the production of high affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci U S A 1998; 95: 6157-6162.
3. de Haard HJ, van Neer N, Reurs A, Hufton SE, Roovers RC, Henderikx P, et al. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem 1999; 274: 18218-18230.
4. Rauchenberger R, Borges E, Thomassen-Wolf E, Rom E, Adar R, Yaniv Y, et al. Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3. J Biol Chem 2003; 278: 38194-38205.
5. Cen XD, Bi Q, Zhu SG. Construction of a large phage display
antibody library by
in vitro package and
in vivo recombination. Appl Microbiol Biotechnol 2006; 71: 767-772.
6. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 1996; 14: 309-314.
7. Griffiths AD, Williams SC, Hartley O, Tomlinson IM, Waterhouse P, Crosby WL, et al. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J 1994; 13: 3245-3260.
8. Sblattero D, Bradbury A. Exploiting recombination in single bacteria to make large phage
antibody libraries. Nat Biotechnol 2000; 18: 75-80.
9. Qiao YY, Wang Y, Chen XS, Wang YX, Hua B. Construction of large single-chain
phage antibody library. J Microbiol Immunol (Chin) 2004; 24: 194-197.
10. Zhang GM, Chen YP, Wang G, Liu YF. Construction and expression of anti-keratin single-chain Fv
antibody. J Cell Mol Immunol (Chin) 2005; 21: 719-722.
11. Sblattero D, Lou J, Marzari R, Bradbury A.
In vivo recombination as a tool to generate molecular diversity in phage
antibody libraries. J Biotechnol 2001; 74: 303-315.
12. Missirlis PI, Smailus DE, Holt RA. A high-throughput screen identifying sequence and promiscuity characteristics of the loxP spacer region in Cre-mediated recombination. BMC Genomics 2006; 7: 73.
13. Holliger P, Prospero T, Winter G. āDiabodiesā: small bivalent and bispecific
antibody fragments. Proc Natl Acad Sci U S A 1993; 90: 6444-6448.
14. Todorovska A, Roovers RC, Dolezal O, Kortt AA, Hoogenboom HR, Hudson PJ. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Methods 2001; 248: 47-66.
15. Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, et al. Prolonged
in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 1998; 77: 1405-1412.
16. Maletz K, Kufer P, Mack M, Raum T, Pantel K, Riethmuller G, et al. Bispecific single-chain antibodies as effective tools for eliminating epithelial cancer cells from human stem cell preparations by redirected cell cytotoxicity. Int J Cancer 2001; 93: 409-416.
17. Sundaresan G, Yazaki PJ, Shively JE, Finn RD, Larson SM, Raubitschek AA, et al.
124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 2003; 44: 1962-1969.
18. Korn T, Muller R, Kontermann RE. Bispecific single-chain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes. J Immunother 2004; 27: 99-106.
19. Asano R, Sone Y, Makabe K, Tsumoto K, Hayashi H, Katayose Y, et al. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent. Clin Cancer Res 2006; 12: 4036-4042.
20. Jimenez X, Lu D, Brennan L, Persaud K, Liu M, Miao H, et al. A recombinant, fully human, bispecific
antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3. Mol Cancer Ther 2005; 4: 427-434.
21. Atwell JL, Breheney KA, Lawrence LJ, McCoy AJ, Kortt AA, Hudson PJ. scFv multimers of the anti-neuraminidase
antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies. Protein Eng 1999; 12: 597-604.
22. Hudson PJ, Kortt AA. High avidity scFv multimers; diabodies and triabodies. J Immunol Methods 1999; 231: 177-189.
23. Le Gall F, Reusch U, Little M, Kipriyanov SM. Effect of linker sequences between the
antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. Protein Eng Des Sel 2004; 17: 357-366.
24. Asvadi P, Fletcher A, Raison RL. Expression and functional analysis of recombinant scFv and diabody fragments with specificity for human RhD. J Mol Recognit 2002; 15: 321-330.
25. Asano R, Kudo T, Nishimura Y, Makabe K, Hayashi H, Suzuki M, et al. Efficient construction of a diabody using a refolding system: anti-carcinoembryonic antigen recombinant
antibody fragment. J Biochem 2002; 132: 903-909.